

JUN 07 2005

400 Garden City Plaza, Ste 300
Garden City, New York 11530
(516) 742-4343 - Telephone
(516) 742-4366 - Facsimile
e-mail: intprop@ssmp.com

**SCULLY, SCOTT, MURPHY
& PRESSER**

Fax

To: Examiner R. S. Landsman
USPTO
Art Unit: 1647
Confirmation No. 9285

From: Xiaochun Zhu, Ph.D.

Fax: (571) 273-8300

Pages: 38 (including cover)

Phone:

Date: June 7, 2005

Re: Ian S. Zagon, et al.
U.S. Patent Application No. 09/431,843
Filed: November 2, 1999
Our Docket: 13038

CC:


☐ **Urgent** ☐ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

The following is being transmitted herewith:


1. Amendment Transmittal (in dup)
2. Amendment Under 37 C.F.R. §1.121
3. Exhibit A
4. Certificate of Transmission by Facsimile (in dup)


CONFIDENTIALITY: The documents accompanying this facsimile transmission may contain information which is either confidential or legally privileged and is intended only for the authorized use of the individual or entity named above without right or publication or republication, dissemination or disclosure except as expressly set forth or established by course of dealing. All rights are reserved. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you received this transmission in error, please notify us immediately by telephone to arrange for return of the documents.

If you have any problems concerning this facsimile, please call (516) 742-4343 and ask for Anna Baerga.


AMENDMENT TRANSMITTAL LETTER (Small Entity)					Docket No. 13038	
Applicant(s): Ian S. Zagon, et al.						
Application No. 09/431,843	Filing Date November 2, 1999	Examiner R. S. Landsman	Customer No. 23389	Group Art Unit 1647	Confirmation No. 9285	
Invention: NOVEL NUCLEIC ACID MOLECULES ENCODING OPIOID GROWTH FACTOR RECEPTORS						
<u>COMMISSIONER FOR PATENTS:</u>				RECEIVED CENTRAL FAX CENTER JUN 07 2005		
Transmitted herewith is an amendment in the above-identified application.						
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27						
The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	24 -	37 =	0	x \$25.00	\$0.00	
INDEP. CLAIMS	4 -	29 =	0	x \$100.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00	
<input checked="" type="checkbox"/> No additional fee is required for amendment.						
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____						
<input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.						
<input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-1013/SSMP						
<input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.						
<input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.						
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.						
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
 _____ Signature			Dated: June 7, 2005			
Xiaochun Zhu Registration No. 56,311 Scully, Scott, Murphy & Presser 400 Garden City Plaza-Site 300 Garden City, New York 11530 (516) 742-4343			<div style="border: 1px solid black; padding: 5px;"><p>I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____</p><p>(Date)</p><p>_____ Signature of Person Mailing Correspondence</p><p>_____ Typed or Printed Name of Person Mailing Correspondence</p></div>			
cc: XZ:ab						

P11SMALL/REV09

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)			Docket No. 13038
Applicant(s): Ian S. Zagon, et al.			
Application No. 09/431,843	Filing Date November 2, 1999	Examiner R. S. Landsman	Group Art Unit 1647
Invention: NOVEL NUCLEIC ACID MOLECULES ENCODING OPIOID GROWTH FACTOR RECEPTORS			
<p>I hereby certify that this <u>Amendment Under 37 C.F.R. 1.121</u> <small>(Identify type of correspondence)</small></p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>(571) 273-8300</u>)</p> <p>on <u>June 7, 2005</u> <small>(Date)</small></p> <div style="text-align: right; margin-top: 100px;"> <p><u>Xiaochun Zhu</u> <small>(Typed or Printed Name of Person Signing Certificate)</small></p> <p> <small>(Signature)</small></p> </div>			
<p>Note: Each paper must have its own certificate of mailing.</p>			

AMENDMENT TRANSMITTAL LETTER (Small Entity)					Docket No. 13038	
Applicant(s): Ian S. Zagon, et al.						
Application No. 09/431,843	Filing Date November 2, 1999	Examiner R. S. Landsman	Customer No. 23389	Group Art Unit 1647	Confirmation No. 9285	
Invention: NOVEL NUCLEIC ACID MOLECULES ENCODING OPIOID GROWTH FACTOR RECEPTORS						
<u>COMMISSIONER FOR PATENTS:</u>				RECEIVED CENTRAL FAX CENTER JUN 07 2005		
Transmitted herewith is an amendment in the above-identified application.						
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27						
The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	24 -	37 =	0	x \$25.00	\$0.00	
INDEP. CLAIMS	4 -	29 =	0	x \$100.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00	
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-1013/SSMP <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
 _____ Signature Xiaochun Zhu Registration No. 56,311 Scully, Scott, Murphy & Presser 400 Garden City Plaza-Site 300 Garden City, New York 11530 (516) 742-4343			Dated: June 7, 2005			
cc: XZ:ab			<div style="border-bottom: 1px solid black; margin-bottom: 5px;">I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ (Date)</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">_____ Signature of Person Mailing Correspondence</div> <div style="border-bottom: 1px solid black;">_____ Typed or Printed Name of Person Mailing Correspondence</div>			

P11SMALL/REV09

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) Applicant(s): Ian S. Zagon, et al.		Docket No. 13038	
Application No. 09/431,843	Filing Date November 2, 1999	Examiner R. S. Landsman	Group Art Unit 1647
Invention: NOVEL NUCLEIC ACID MOLECULES ENCODING OPIOID GROWTH FACTOR RECEPTORS			
<p>I hereby certify that this <u>Amendment Under 37 C.F.R. 1.121</u> <i>(Identify type of correspondence)</i></p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>(571) 273-8300</u>)</p> <p>on <u>June 7, 2005</u> <i>(Date)</i></p> <div style="text-align: right; margin-top: 100px;"> <u>Xiaochun Zhu</u> <i>(Typed or Printed Name of Person Signing Certificate)</i>  <i>(Signature)</i> </div>			
Note: Each paper must have its own certificate of mailing.			

RECEIVED
CENTRAL FAX CENTER

: 5167424366

6 / 38

JUN 07 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Ian S. Zagon, et al.	Examiner:	R. S. Landsman
Serial No.:	09/431,843	Art Unit:	1647
Filed:	November 2, 1999	Docket:	13038
For:	NOVEL NUCLEIC ACID MOLECULES ENCODING OPIOID GROWTH FACTOR RECEPTORS	Dated:	June 7, 2005


Confirmation No.: 9285Commissioner for Patents
Alexandria, VA 22313-1450**AMENDMENT UNDER 37 C.F.R. §1.121**

Sir:

In response to the Office Action dated May 3, 2005 and in accordance with 37 C.F.R. §1.121, Applicants submit the following amendment for entry in the above-identified case.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Dated: June 7, 2005
Xiaochun Zhu

H:\work\1521\13038\amend\13038.am4.doc